Forbion Capital Partners

Forbion Capital Partners is a prominent European venture capital firm exclusively focused on the life sciences sector. Headquartered in Naarden, The Netherlands, with an additional office in Munich, Germany, Forbion specializes in investing in innovative drug discovery and development companies. Their strategic approach aims to identify and nurture promising biopharmaceutical ventures from early-stage research through clinical development, contributing significantly to the advancement of medical science.

The firm's investment strategy is centered on leading or co-leading financing rounds for companies with high-potential therapeutic assets. Forbion typically makes initial investments ranging from approximately €5 million to €15 million (equivalent to about $5.4 million to $16.2 million USD, based on recent exchange rates). They are known for their hands-on approach, providing not only capital but also strategic guidance, operational expertise, and access to a vast network within the pharmaceutical and biotech industries. This comprehensive support is designed to help portfolio companies navigate the complex landscape of drug development and achieve key milestones.

Forbion has demonstrated substantial fundraising success, underscoring its significant capital deployment capacity. In late 2023, the firm announced the final close of its Forbion VI fund at €600 million, making it one of the largest dedicated life sciences venture capital funds in Europe. This substantial capital pool, alongside previous funds like Forbion V which closed at €460 million, enables the firm to provide robust follow-on funding, supporting its portfolio companies throughout their growth trajectory and ensuring they have the necessary resources to bring novel therapies to market.

With a strong track record of successful exits, including IPOs and M&A transactions, Forbion has established itself as a key player in the European life sciences investment landscape. Their commitment to fostering groundbreaking innovation and their deep scientific and commercial expertise position them as a preferred partner for entrepreneurs in the biotechnology and pharmaceutical sectors. The firm's long-term vision and patient capital approach are crucial in the capital-intensive and lengthy process of drug development, aiming to deliver both significant returns for investors and impactful solutions for patients.